These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 10598311)

  • 1. [Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability].
    Gury C; Cousin F
    Encephale; 1999; 25(5):470-6. PubMed ID: 10598311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
    van Harten J
    Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C; Härtter S
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
    Sánchez C; Hyttel J
    Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P; Rochat B
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
    Preskorn S
    Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():13-9. PubMed ID: 7963446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacogenetics of the selective serotonin reuptake inhibitors.
    Brøsen K
    Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SSRI differentiation: Pharmacology and pharmacokinetics.
    Leonard BE
    Hum Psychopharmacol; 1995 Oct; 10 Suppl 3(S3):S149-S158. PubMed ID: 29569414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology.
    Goodnick PJ; Goldstein BJ
    J Psychopharmacol; 1998; 12(3 Suppl B):S5-20. PubMed ID: 9808077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in interactions of SSRIs.
    Brøsen K
    Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
    Caccia S
    Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and guide to selection of selective serotonin reuptake inhibitors.
    Edwards JG; Anderson I
    Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Care of depression in the elderly: comparative pharmacokinetics of SSRIs.
    Baumann P
    Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S35-43. PubMed ID: 9817619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
    Liston HL; DeVane CL; Boulton DW; Risch SC; Markowitz JS; Goldman J
    J Clin Psychopharmacol; 2002 Apr; 22(2):169-73. PubMed ID: 11910262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.